Nicholas McAndrew, MD, MSCE, shares his perspectives on the updated overall survival results from the phase 3 MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with fulvestrant plus or minus ribociclib.
Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer
Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.
Nicholas McAndrew, MD, MSCE, discusses the impact of CDK4/6 therapy duration on alpelisib benefit in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer from the BYLieve trial.
Nicholas McAndrew, MD, MSCE, provides his perspective on real-world clinical outcomes using alpelisib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.
Nicholas McAndrew, MD, MSCE, provides final thoughts on findings reported at ASCO 2021 for patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5